EXABS-225-NQ Next Questions: Mantle Cell Lymphoma

Kami Maddocks

doi:10.1016/S2152-2650(22)00688-7

EXABS-225-NQ Next Questions: Mantle Cell Lymphoma

Kami Maddocks

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	S113-S114
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	22
DOIs	https://doi.org/10.1016/S2152-2650(22)00688-7
State	Published - Oct 2022

Keywords

BCL-2 inhibitor
Bruton's tyrosine kinase inhibitor (BTKi)
antibody drug conjugates (ADC)
chimeric antigen receptor (CAR) T cells
minimal residual disease (MRD)

Access to Document

10.1016/S2152-2650(22)00688-7

Cite this

@article{8525344157a54de3acd8d1289378cfba,

title = "EXABS-225-NQ Next Questions: Mantle Cell Lymphoma",

keywords = "BCL-2 inhibitor, Bruton's tyrosine kinase inhibitor (BTKi), antibody drug conjugates (ADC), chimeric antigen receptor (CAR) T cells, minimal residual disease (MRD)",

author = "Kami Maddocks",

year = "2022",

month = oct,

doi = "10.1016/S2152-2650(22)00688-7",

language = "English",

volume = "22",

pages = "S113--S114",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

}

TY - JOUR

T1 - EXABS-225-NQ Next Questions

T2 - Mantle Cell Lymphoma

AU - Maddocks, Kami

PY - 2022/10

Y1 - 2022/10

KW - BCL-2 inhibitor

KW - Bruton's tyrosine kinase inhibitor (BTKi)

KW - antibody drug conjugates (ADC)

KW - chimeric antigen receptor (CAR) T cells

KW - minimal residual disease (MRD)

UR - https://www.scopus.com/pages/publications/85138163692

U2 - 10.1016/S2152-2650(22)00688-7

DO - 10.1016/S2152-2650(22)00688-7

M3 - Article

C2 - 36163710

AN - SCOPUS:85138163692

SN - 2152-2650

VL - 22

SP - S113-S114

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

ER -

EXABS-225-NQ Next Questions: Mantle Cell Lymphoma

Keywords

Access to Document

Other files and links

Cite this